{"id":"W4221092886","doi":"10.1016/j.esmoop.2022.100419","title":"Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Merck Sharp and Dohme; Genentech; Novartis Farmacéutica; Servier; Oncolytics Biotech; Else Kröner-Fresenius-Stiftung; Cancer Research UK; AstraZeneca España; Tessa Therapeutics; Eli Lilly and Company; Boehringer Ingelheim España; Novartis; Celgene; Roche España; F. Hoffmann-La Roche; Roche; NordForsk; Ernst Schering Foundation; GlaxoSmithKline España; Wilhelm Sander-Stiftung; Amgen; Pfizer; Bristol-Myers Squibb; Sanofi; MedImmune; Merck","keywords":"Medicine; Atezolizumab; Internal medicine; Clinical endpoint; Interim analysis; Hazard ratio; Lung cancer; Oncology; Surgery; Cancer; Confidence interval; Clinical trial; Gastroenterology; Pembrolizumab; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004442608,0.002257837,0.002399682,0.0007324486,0.0005882764,0.00137189,0.0009586539,0.001179033,0.004604267],"category_scores_gemma":[0.001640713,0.0009857345,0.001605842,0.0007370025,0.0007635328,0.001163119,0.0009363234,0.002807118,0.001051323],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001145643,"about_ca_system_score_gemma":0.002634381,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001138677,"about_ca_topic_score_gemma":0.001846336,"domain_scores_codex":[0.9991692,0.0004059634,0.00004770983,0.0001447808,0.0001000836,0.0001322069],"domain_scores_gemma":[0.9986351,0.0001486889,0.0002944229,0.000196064,0.0001360281,0.0005896384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7995363,0.0919429,0.01495329,0.000656809,0.002367343,0.0002119468,0.0002263976,0.002714255,0.02107468,0.0005125683,0.008422599,0.05738096],"study_design_scores_gemma":[0.7486255,0.2296884,0.01359125,0.00002804872,0.0006431444,0.0002732823,0.00005894223,0.001342761,0.001857293,0.0003876566,0.003456836,0.00004690477],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843768,0.00142198,0.00120901,0.0004930421,0.0001929405,0.007563239,0.003181599,0.0001768402,0.001384593],"genre_scores_gemma":[0.9728319,0.001686569,0.004357608,0.00116564,0.0002889051,0.009970355,0.006068152,0.00007651866,0.003554436],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004604267,"threshold_uncertainty_score":0.02349502,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09255978133815697,"score_gpt":0.4642404448781073,"score_spread":0.3716806635399503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}